Figure 3.

Kaplan–Meier survival analyses in patients treated with valrubicin for (a) EFS*; (b) PFS^$; (c) WFS^‡; (d) CFS^§.

*An event was defined as recurrence, progression, or death from any cause. Dashed lines depict the median EFS time (3.5 months). ^$Disease progression is defined as progression to muscle-invasive disease (stage T2 or higher) confirmed by biopsy, and PFS time was defined as the number of days from the date of the first valrubicin dose to the date of progression recorded on the effectiveness outcomes form. Dashed lines depict the median PFS time (18.2 months). PFS 95% CIs were NC at 21 months. ^‡Defined as recurrence, progression, cystectomy, change of antibladder cancer therapy, or death from any cause. ^§Time to cystectomy was the number of days between the first dose of valrubicin and cystectomy. For patients who did not undergo cystectomy, the censoring date was the start of other antibladder cancer therapy or, for those who did start another antibladder cancer therapy, the last visit. Median CFS could not be calculated.

CFS, cystectomy-free survival; CI, confidence interval; EFS, event-free survival; NC, not calculable; PFS, progression-free survival; WFS, worsening-free survival.